Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.wockhardt.com | |
Market Cap | 8,951.71 Cr. | |
Enterprise Value(EV) | 10,870.71 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -32.72 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.54 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 210.88 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 2.77 | Calculated using Price: 583.55 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 15.34 Cr. | 153,400,936 Shares |
FaceValue | 5 | |
About Wockhardt Ltd. | ||
The company is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. It has many research centres and several manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines. It is a business in transition. New and innovative business models are in motion to make the most of emerging opportunities. A new drive for growth today permeates every mind-set, process and techno-innovation within Wockhardt. |
1 Day |
|
+4.99% |
1 Week |
|
+7.24% |
1 Month |
|
-3.21% |
3 Month |
|
+39.76% |
6 Month |
|
+150.61% |
1 Year |
|
+286.20% |
2 Year |
|
+93.10% |
5 Year |
|
+47.44% |
10 Year |
|
+39.96% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 12.49 | 7.07 | -6.42 | -21.81 | -11.43 | -5.22 | -9.92 | -7.77 | -17.32 | |
Return on Capital Employed (%) | 11.25 | 6.87 | -0.31 | -5.47 | -2.87 | -1.11 | -5.5 | -1.96 | -5.88 | |
Return on Assets (%) | 5.84 | 3.25 | -2.69 | -7.93 | -4.01 | -1.8 | -3.93 | -3.71 | -8.42 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 3,715 | 3,775 | 3,337 | 2,852 | 2,675 | 2,672 | 3,376 | 3,849 | 3,354 | 3,125 | |
Non Curr. Liab. | 1,872 | 1,893 | 3,151 | 2,089 | 1,703 | 1,195 | 496 | 261 | -22 | 739 | |
Curr. Liab. | 1,773 | 1,842 | 1,979 | 2,692 | 2,864 | 3,497 | 3,121 | 3,207 | 3,435 | 2,685 | |
Minority Int. | 144 | 465 | 382 | 346 | 330 | 386 | 383 | 353 | 308 | 307 | |
Equity & Liab. | 7,505 | 7,976 | 8,849 | 7,978 | 7,571 | 7,749 | 7,376 | 7,670 | 7,075 | 6,856 | |
Non Curr. Assets | 3,983 | 4,024 | 4,314 | 4,599 | 4,756 | 5,320 | 4,951 | 5,081 | 4,867 | 4,819 | |
Curr. Assets | 3,522 | 3,952 | 4,535 | 3,380 | 2,815 | 2,401 | 2,281 | 2,445 | 1,914 | 2,037 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 7,505 | 7,976 | 8,849 | 7,978 | 7,571 | 7,749 | 7,376 | 7,670 | 7,075 | 6,856 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 4,482 | 4,453 | 4,015 | 3,937 | 3,566 | 2,844 | 2,708 | 3,230 | 2,651 | 2,776 | |
Other Income | 67 | 66 | 114 | 177 | 21 | 60 | 132 | 20 | 122 | 78 | |
Total Income | 4,548 | 4,519 | 4,129 | 4,114 | 3,587 | 2,904 | 2,840 | 3,250 | 2,773 | 2,854 | |
Total Expenditure | -3,772 | -3,959 | -4,002 | -3,992 | -3,604 | -2,746 | -2,771 | -2,932 | -2,550 | -2,648 | |
PBIDT | 776 | 560 | 127 | 122 | -17 | 158 | 69 | 318 | 223 | 206 | |
Interest | -55 | -129 | -225 | -255 | -265 | -276 | -249 | -299 | -302 | -308 | |
Depreciation | -145 | -142 | -149 | -150 | -164 | -224 | -246 | -247 | -251 | -221 | |
Taxation | -163 | -38 | 21 | -26 | 135 | 204 | 271 | 132 | 3 | -99 | |
Exceptional Items | -358 | -142 | -183 | -294 | -110 | ||||||
PAT | 413 | 252 | -226 | -667 | -312 | -138 | -297 | -279 | -621 | -532 | |
Minority Interest | -8 | -2 | 30 | 59 | 22 | -26 | -2 | 35 | 62 | 30 | |
Share Associate | 1 | ||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 405 | 251 | -196 | -608 | -195 | -69 | 686 | -244 | -559 | -502 | |
Adjusted EPS | 34 | 21 | -16 | -51 | -16 | -6 | 57 | -17 | -39 | -35 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 1,476 | 355 | 72 | -269 | 68 | 183 | 649 | -287 | 413 | 153 | |
Cash Fr. Inv. | -852 | -207 | -818 | -687 | 630 | 95 | -156 | 1,470 | -201 | -125 | |
Cash Fr. Finan. | -601 | -76 | 254 | 1,254 | -769 | -776 | -680 | -1,171 | -71 | -315 | |
Net Change | 23 | 73 | -492 | 298 | -71 | -499 | -186 | 12 | 141 | -287 | |
Cash & Cash Eqvt | 1,102 | 1,159 | 665 | 964 | 897 | 397 | 219 | 232 | 370 | 90 |
Thu, 28 Mar 2024
Closure of Trading Window This is to inform you that pursuant to Companys Code of Conduct for regulating monitoring and reporting trading by designated person the trading window for dealing in the equity shares of the Company will be closed from 1st April 2024 untill 48 hours of declaration of audited Financial Results of the Company for the financial year ended 31st March 2024. |
Tue, 26 Mar 2024
Board Meeting Outcome for Outcome Of The Meeting Of The Capital Raising Committee The Capital Raising Committee of the Company has at its meeting held today i.e. Tuesday 26th March 2024 inter alia: approved the closure of Issue today i.e. Tuesday 26th March 2024 and determined the allocation of 92 85 163 Equity Shares at an issue price of ?517/- per Equity Share (including a premium of ?512/- per Equity Share) which includes a discount of ?27.02/- per Equity Share equivalent to 4.97% to the floor price of ?544.02/- per Equity Share determined as per the formula prescribed under Regulation 176(1) of the SEBI ICDR Regulations for the Equity Shares to be allotted to the eligible QIBs in the Issue; approved and adopted the placement document dated 26th March 2024 (Placement Document) in connection with the Issue; and approved and finalized the confirmation of allocation note for sending to such QIBs to whom the allocation of Equity Shares pursuant to the issue is to be confirmed; |
Tue, 26 Mar 2024
Announcement under Regulation 30 (LODR)-Allotment The Capital raising Committee of the Company in its meeting held today i.e. 26th March 2024 approved the issue and allotment of 92 85 163 Equity Shares to eligible QIBs. |
Thu, 28 Mar 2024 |
Close Crossing Last Week High |
Closing Above Previous High |
Making Higher Highs for 3 days |
Close Within 52 Week High Zone |
Close Above Last Week High |